Sugi Predict

Sugi Predict / Compounds / SCHEMBL10115524

SCHEMBL10115524

SCHEMBL10115524

CC(C)S(=O)(=O)NCCCCC(=O)Nc1ccc(OCC2CCCCO2)cc1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 8/20 0.50
▸ SMN1; SMN2 Q16637 7/20 0.50
▸ NPC1 O15118 6/20 0.50
▸ LMNA P02545 2/20 0.50
▸ ALDH1A1 P00352 2/20 0.47
▸ ACACB O00763 1/20 0.46
▸ TP53 P04637 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ CASP3 P42574 1/20 0.43
▸ SENP7 Q9BQF6 1/20 0.43
▸ POLB P06746 3/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ MAPT P10636 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10115250 0.87 RAB9A (0.52) RAB9ASMN1; SMN2NPC1LMNAALDH1A1
SCHEMBL13564984 0.86 RAB9A (0.47) RAB9ASMN1; SMN2NPC1LMNAALDH1A1
SCHEMBL10115495 0.85 L3MBTL1 (0.45) LMNAALDH1A1ACACBPOLBTDP1
SCHEMBL10115491 0.81 ALDH1A1 (0.47) SMN1; SMN2LMNAALDH1A1ACACBHTT
SCHEMBL10115453 0.80 ALDH1A1 (0.49) SMN1; SMN2LMNAALDH1A1HTTTDP1
SCHEMBL10116734 0.79 RAB9A (0.68) RAB9ASMN1; SMN2NPC1LMNAALDH1A1
SCHEMBL10114706 0.78 HRH3 (0.49) SMN1; SMN2LMNAALDH1A1ACACBTDP1
SCHEMBL10113763 0.78 L3MBTL1 (0.58) SMN1; SMN2LMNAALDH1A1POLBMAPT
SCHEMBL13204443 0.77 RAB9A (0.51) RAB9ASMN1; SMN2NPC1LMNAALDH1A1
SCHEMBL10114968 0.77 RAB9A (0.51) RAB9ASMN1; SMN2NPC1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R RAB9A 3699/4885SMN1; SMN2 2213/4885NPC1 1435/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R RAB9A 3651/4885SMN1; SMN2 2197/4885NPC1 1353/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R RAB9A 3820/4885SMN1; SMN2 2251/4885NPC1 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.